Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | DREAMM-9: belantamab mafodotin plus VRd vs VRd in TI NDMM

Saad Usmani • 27 May 2020
ASCO 2020
Multiple Myeloma Belantamab mafodotin Bortezomib Lenalidomide
DREAMM-9

Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, highlights data from the DREAMM-9 study (NCT04091126). This phase III study assessed the efficacy and safety of belantamab mafodotin plus VRd versus VRd alone in patients with transplant-ineligible newly diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Saad Usmani

1:14
Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myeloma
Saad Usmani • 8 Sep 2023
1:53
MajesTEC‐1 update: rates of infection in patients with myeloma receiving teclistamab
Saad Usmani • 8 Sep 2023
1:43
High-risk multiple myeloma: addressing challenges and unmet needs
Saad Usmani • 8 Sep 2023
2:05
Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma
Saad Usmani • 25 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals